Skip to main content
Equibles

BARCLAYS PLC

Position in PFE — Pfizer Inc

CIK 312069 LONDON, X0
Back to PFE Full portfolio

Position in PFE

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$403,262,965
-$9,209,403 QoQ
Shares Held
16,746,801
+14.0% QoQ
Ownership
0.294%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#37
of 2,820 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 99% Shared 0% None 1%

Common Shares in PFE Over Time

Shares Held

Position Value (USD)

Derivatives in PFE

reported options exposure · as of Jun 30, 2026
CallValue
$8,257,032
CallShares
342,900
PutValue
$168,280,672
PutShares
6,988,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

BARCLAYS PLC holds $8,073,972,287 across 18 Drug Manufacturers - General names. PFE ranks #8 (5.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 1,143,891 $1,372,017,294
2 ABBV
AbbVie Inc.
 5,015,515 $1,262,104,193
3 AZN
Astrazeneca PLC
 6,592,403 $1,250,051,454
4 JNJ
Johnson & Johnson
 4,651,595 $1,181,365,579
5 MRK
Merck & Co., Inc.
 6,793,897 $873,015,763
6 GILD
Gilead Sciences, Inc.
 5,113,242 $646,006,993
7 AMGN
Amgen Inc
 1,326,673 $480,414,824
8 PFE
Pfizer Inc
This page 		16,746,801 $403,262,965

All Filings in PFE

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $8,257,032 342,900
2026-06-30 $168,280,672 6,988,400
2026-06-30 $403,262,965 16,746,801
2026-03-31 $13,840,632 492,900
2026-03-31 $412,472,368 14,689,187
2026-03-31 $4,495,608 160,100
2025-12-31 $82,794,990 3,325,100
2025-12-31 $65,621,460 2,635,400
2025-12-31 $451,536,323 18,133,989
2025-09-30 $7,264,348 285,100
2025-09-30 $34,217,092 1,342,900
2025-09-30 $472,540,815 18,545,558
2025-06-30 $78,413,976 3,234,900
2025-06-30 $377,540,131 15,575,088
2025-03-31 $378,025,715 14,918,142
2025-03-31 $5,164,292 203,800
2025-03-31 $163,612,778 6,456,700
2024-12-31 $61,690,209 2,325,300
2024-12-31 $447,837,248 16,880,409
2024-12-31 $7,680,435 289,500
2024-09-30 $8,378,130 289,500
2024-09-30 $23,247,502 803,300
2024-09-30 $783,802,680 27,083,714
2024-06-30 $426,493,793 15,242,809
2024-06-30 $138,120,472 4,936,400
2024-06-30 $4,896,500 175,000
2024-03-31 $2,081,250 75,000
2024-03-31 $598,437,241 21,565,306
2023-12-31 $6,477,750 225,000
2023-12-31 $334,699,696 11,625,554
2023-12-31 $22,744,100 790,000
2023-09-30 $534,991,862 16,128,787
2023-09-30 $9,287,600 280,000
2023-06-30 $22,426,152 611,400
2023-06-30 $477,789,826 13,025,895
2023-06-30 $9,067,296 247,200
2023-03-31 $34,100,640 835,800
2023-03-31 $267,616,378 6,559,225
2023-03-31 $22,823,520 559,400
2022-12-31 $640,524,798 12,500,484
2022-12-31 $40,315,632 786,800
2022-12-31 $27,951,420 545,500
2022-09-30 $13,355,552 305,200
2022-09-30 $402,153,741 9,189,985
2022-06-30 $24,872,792 474,400
2022-06-30 $9,437,400 180,000
2022-06-30 $377,331,104 7,196,855
2022-03-31 $586,133,622 11,321,878
2021-12-31 $69,602,235 1,178,700
2021-12-31 $3,814,630 64,600

Report a Problem

Category
Description
Email (optional, for follow-up)